leisure time -WSS

leisure time

author：explore 2025-09-27 10:05:06 - browse：34282

This is the inaugural edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Hello! Welcome to the premiere issue of Adam’s Biotech Scorecard. I’m excited to get started. Let’s do this! (By the way, the AF in the logo are my initials, not the “other” AF.)

The contrarian view of Viking Therapeutics

Closeup financial chart

The developer of a dual-acting GLP-1/GIP treatment for obesity is riding high on positive data and takeout speculation. The drug, called VK2735, has shown impressive weight loss with minimal gastrointestinal side effects in both subcutaneous and oral formulations, positioning it as a strong challenger to the obesity juggernauts from Eli Lilly and Novo Nordisk. With a stock price that has soared nearly 800% over the past year, Viking is now a $9 billion company and a prime acquisition target for a cash-rich pharma company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： David Liu startup to focus on CRISPR delivery

hotspot

WSS

The struggle to figure out which patients 'deserve' Wegovy

PBMs drew scrutiny in House hearing — and so did pharma

Akili changes sales model for its ADHD video game treatment

Testing for cancer recurrence creates a new limbo for patients

First Opinion Podcast: How to protect health care in times of war

People with substance use disorder deserve online privacy

hotspot

leisure time

The contrarian view of Viking Therapeutics

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

House panel takes first step toward fixing drug shortages

Duchenne breakthrough therapy leaves behind pioneering families

House panel takes first step toward fixing drug shortages

Activists slam private health insurers over coverage restrictions

'A game

As demand for Covid shots wanes, Moderna seeks its next success

David Liu startup to focus on CRISPR delivery

Hepatitis C has a cure — but many Americans still lack access to it

Covid’s new normal has set in amid another rise in cases

focus

Eli Lilly CEO gives to Mike Pence presidential super PAC

Why Sanofi got shellacked over its spinoff

Readout Newsletter: XBI biotech index, Akero Therapeutics

Meta's Zuckerberg and Chan on track to put $50 billion into science

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Readout Newsletter: What happened with Sarepta's Duchenne data

explore

hotspot

hotspot

explore